新型钙调神经磷酸酶抑制药伏环孢素临床研究进展

Research progress in clinical application of a novel calcineurin inhibitor:voclosporin

伏环孢素是一种口服新型钙调神经磷酸酶抑制药,是环孢素A的衍生物,主要用于治疗自身免疫性疾病,如银屑病、非感染性葡萄膜炎和器官移植后排斥反应。2021年1月,基于两个Ⅱ期和Ⅲ期临床试验的积极结果,FDA批准伏环孢素与标准治疗方案联合用于治疗成人活动性狼疮肾炎。目前,也有研究在探索伏环孢素用于新型冠状病毒感染的肾移植患者。本文对伏环孢素的作用机制、药动学和药效学、用法用量、联合用药和疾病中应用进行归纳总结,为其临床用药提供参考。

Voclosporin,an analogue of cyclosporine A,is an oral novel calcineurin inhibitor for autoimmune diseases such as plaque psoriasis,non-infectious uveitis and prevention of renal transplant rejection.Based on positive results from two pivotal phaseⅡandⅢclinical trials,voclosporin was aproved by FDA in January 2021 for adult patients with active lupus nephritis in combination with a standrand treatment regimen.Recently,voclosporin has been explored for kidney transplant recipients with corona virus disease 2019(COVID-19).This article summarized the mechanism of action,pharmacokinetics and pharmacodynamics,dosage,co-administration and indisease application of voclosporin in clinical treatment.